Achillion is not likely to develop an all-oral Hep C therapy on its own, which is why the company needs to be as deal friendly as possible.
"None of the major players in the Hep C field can lay claim today to having everything they need," said Kishbauch, explaining why he thinks Hep C deal activity is about to accelerate.
He's right. The big Hep C players -- Roche, Merck, Vertex, Bristol-Myers Squibb (BMY) -- could all benefit from bringing in new drugs. It remains to be seen, however, if Achillion has what these guys want.
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV